CN115209885A - γ-羟基丁酸盐(GHB)给药 - Google Patents

γ-羟基丁酸盐(GHB)给药 Download PDF

Info

Publication number
CN115209885A
CN115209885A CN202080097472.7A CN202080097472A CN115209885A CN 115209885 A CN115209885 A CN 115209885A CN 202080097472 A CN202080097472 A CN 202080097472A CN 115209885 A CN115209885 A CN 115209885A
Authority
CN
China
Prior art keywords
oxybate
mixed
hydroxybutyrate
patient
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080097472.7A
Other languages
English (en)
Chinese (zh)
Inventor
F·斯科比兰达
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jazz Pharmaceuticals Ireland Ltd
Original Assignee
Jazz Pharmaceuticals Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jazz Pharmaceuticals Ireland Ltd filed Critical Jazz Pharmaceuticals Ireland Ltd
Publication of CN115209885A publication Critical patent/CN115209885A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
CN202080097472.7A 2019-12-24 2020-12-22 γ-羟基丁酸盐(GHB)给药 Pending CN115209885A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962953288P 2019-12-24 2019-12-24
US62/953288 2019-12-24
US202062993372P 2020-03-23 2020-03-23
US62/993372 2020-03-23
US202063000547P 2020-03-27 2020-03-27
US63/000547 2020-03-27
US202063052676P 2020-07-16 2020-07-16
US63/052676 2020-07-16
PCT/US2020/066561 WO2021133778A1 (en) 2019-12-24 2020-12-22 Gamma-hydroxybutyrate (ghb) dosing

Publications (1)

Publication Number Publication Date
CN115209885A true CN115209885A (zh) 2022-10-18

Family

ID=74191949

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080097472.7A Pending CN115209885A (zh) 2019-12-24 2020-12-22 γ-羟基丁酸盐(GHB)给药

Country Status (14)

Country Link
US (3) US20210186907A1 (https=)
EP (1) EP4081204A1 (https=)
JP (1) JP2023508975A (https=)
KR (1) KR20220119429A (https=)
CN (1) CN115209885A (https=)
AU (1) AU2020414694A1 (https=)
BR (1) BR112022012594A2 (https=)
CA (1) CA3162974A1 (https=)
CL (1) CL2022001743A1 (https=)
CO (1) CO2022010330A2 (https=)
IL (1) IL294176A (https=)
MX (1) MX2022007968A (https=)
TW (1) TW202135790A (https=)
WO (1) WO2021133778A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX391660B (es) 2010-03-24 2025-03-21 Jazz Pharmaceuticals Inc Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
BR112021006027A2 (pt) 2018-11-19 2021-06-29 Jazz Pharmaceuticals Ireland Limited formulações de fármaco resistente a álcool
CN113473980A (zh) 2019-03-01 2021-10-01 弗拉梅尔爱尔兰有限公司 在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物
TW202139986A (zh) 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 治療原發性嗜睡症之方法
US12582622B2 (en) 2020-10-08 2026-03-24 Jazz Pharmaceuticals Ireland Limited Sodium oxybate to treat idiopathic hypersomnia
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020077334A1 (en) * 1998-12-23 2002-06-20 Harry N. Cook Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
CN105025892A (zh) * 2012-12-14 2015-11-04 杰资制药爱尔兰有限公司 γ-羟基丁酸盐组合物及其治疗疾病的用途
US20180263936A1 (en) * 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2383673T3 (es) 2000-09-22 2012-06-25 Jpi Commercial, Llc Composiciones de gamma-hidroxibutirato que contienen portadores de hidrato de carbonos
US7610153B2 (en) * 2002-02-13 2009-10-27 Virginia Commonwealth University Multi-drug titration and evaluation
US7668730B2 (en) 2002-12-17 2010-02-23 JPI Commercial, LLC. Sensitive drug distribution system and method
US8778398B2 (en) 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
US8771735B2 (en) 2008-11-04 2014-07-08 Jazz Pharmaceuticals, Inc. Immediate release dosage forms of sodium oxybate
CN102946869B (zh) * 2010-05-04 2016-08-03 爵士制药有限公司 γ-羟基丁酸的速释制剂及剂型
US9050302B2 (en) 2013-03-01 2015-06-09 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
US9801852B2 (en) 2013-08-30 2017-10-31 Jazz Pharmaceuticals, Inc. Devices and methods for facilitating and controlling use of a medication

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020077334A1 (en) * 1998-12-23 2002-06-20 Harry N. Cook Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
CN105025892A (zh) * 2012-12-14 2015-11-04 杰资制药爱尔兰有限公司 γ-羟基丁酸盐组合物及其治疗疾病的用途
US20180263936A1 (en) * 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders

Also Published As

Publication number Publication date
WO2021133778A1 (en) 2021-07-01
IL294176A (en) 2022-08-01
US20210186907A1 (en) 2021-06-24
JP2023508975A (ja) 2023-03-06
EP4081204A1 (en) 2022-11-02
CO2022010330A2 (es) 2022-10-21
BR112022012594A2 (pt) 2022-09-06
US20240285560A1 (en) 2024-08-29
KR20220119429A (ko) 2022-08-29
AU2020414694A1 (en) 2022-08-18
US20210361601A1 (en) 2021-11-25
TW202135790A (zh) 2021-10-01
CL2022001743A1 (es) 2023-02-10
CA3162974A1 (en) 2021-07-01
MX2022007968A (es) 2022-09-02

Similar Documents

Publication Publication Date Title
CN115209885A (zh) γ-羟基丁酸盐(GHB)给药
US11426373B2 (en) Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
US6417206B1 (en) Antitussive/antihist aminic/decongestant compositions
RU2010136935A (ru) Фармацевтические композиции энтакапона, леводопы и карбидопы с улучшенной биодоступностью
EP2474309B1 (en) Pharmaceutical composition comprising ibuprofen, tramadol and a basic amino acid, preparation method thereof and use of same
JP2019112424A (ja) トホグリフロジンを含有する固形製剤及びその製造方法
JPH04159223A (ja) 止瀉剤組成物
KR20210105343A (ko) 폐동맥 고혈압 및 관련 폐동맥 고혈압의 치료 방법
CN117858869A (zh) 2-氨基-2-(2-(1-癸基-1h-1,2,3-三唑-4-基)乙基)丙烷-1,3-二醇的新盐以及包含其的药物组合物
CN109893502A (zh) 一种枸橼酸托法替布组合物及其制备方法
CN116585261B (zh) 药物液体组合物及其制备方法和应用
US20220370391A1 (en) Compounds Comprising Curcumin and Basic Amino Acids
US7786168B2 (en) Phenolic acid salts of gabapentin in solid dosage forms and methods of use
WO2020238885A1 (zh) 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物的治疗方法
CN119868549A (zh) 含有缺氧诱导因子-脯酰胺羟基化酶抑制剂的长效口服药物及其应用
US9271951B2 (en) Levothyroxine formulation with acacia
US20010011104A1 (en) Antihistamine compositions
WO2012150607A2 (en) Oral liquid composition comprising divalproex sodium and process for preparing thereof
KR20040010666A (ko) ２ 형 인슐린 내성 당뇨병 환자의 치료를 위한 비오틴과회합된 아세틸 ｌ-카르니틴의 용도
CN114929682A (zh) 苯并硫代吡喃酮类化合物的盐及其制备方法和用途
US20070248667A1 (en) Tannate Compositions and Methods of Use
JP2024541770A (ja) 神経障害の治療方法
CA3221594A1 (en) Extended-release compositions of mexiletine for oral administration
TW202527911A (zh) 用於治療猝睡症的化合物
JPH11322604A (ja) ジフェニルピペラジン化合物を含有する製剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20221018